Mai Kien T, Truong Luan D, Ball Christopher G, Williams Phillip, Flood Trevor A, Belanger Eric C
The Ottawa Hospital, Ottawa, ON, Canada; University of Ottawa, Pathology and Laboratory Medicine, Ottawa, ON, Canada.
Department of Pathology and Genomic Medicine, The Methodist Hospital Physician Organization, Weill Cornell Medical College of Cornell University, United States.
Pathol Res Pract. 2015 Aug;211(8):610-8. doi: 10.1016/j.prp.2015.05.005. Epub 2015 May 27.
We characterize invasive urothelial carcinoma (UC) exhibiting urothelial basal cell immunohistochemical markers. Consecutive invasive UCs were immunostained with CK20 and urothelial basal cell markers, cytokeratin 5 (CK5)/CD44. Immunostaining for CK5 and CD44 was scored as follows: positive for staining of more than 25% thickness of the epithelial nest or epithelium and low for lesser immunoreactivity. Invasive urothelial carcinoma (UC) exhibiting positive CK5/CD44 staining was designated as basal-like UC (BUC). In this study, of 251 invasive UC (pT1 in 57% and pT2-4 in 43%), BUC accounted for 40% of cases (accounting for most pT2-4 UC) and often presented as non-papillary UC without previous history of UC. In addition, BUC exhibited uniform nuclei with lesser degree of atypia than non BUC and decreased or negative cytokeratin 20 reactivity. Nested and microcystic variants of UC immunohistochemically stained as BUCs. Invasive non-BUCs were often papillary with marked cytologic atypia and pleomorphism, and accounted for most pT1 UC. The rates of perivesical invasion, lymph node and distant metastases were higher for BUC than non-BUC. All nine cases with absent/minimal residual in situ UC in 102 radical cystectomy specimens were from invasive non-BUC. BUC is distinguished from non-BUC due to this aggressive behavior, distinct immunohistochemical profile, and predominant non-papillary architecture. Our findings are consistent with recent studies identifying a subtype of muscle-invasive UC with molecular expression of basal cell and luminal cell molecular profiles. Our study further supports categorizing invasive UCs into these subtypes with different biological behaviors, possibly contributing to better therapeutic strategies.
我们对表现出尿路上皮基底细胞免疫组化标志物的浸润性尿路上皮癌(UC)进行了特征描述。对连续的浸润性UC进行细胞角蛋白20(CK20)和尿路上皮基底细胞标志物细胞角蛋白5(CK5)/CD44免疫染色。CK5和CD44的免疫染色评分如下:上皮巢或上皮厚度超过25%染色阳性,免疫反应性较低则为低表达。CK5/CD44染色阳性的浸润性尿路上皮癌(UC)被指定为基底样UC(BUC)。在本研究中,251例浸润性UC(57%为pT1,43%为pT2 - 4)中,BUC占40%(占大多数pT2 - 4 UC),且常表现为无UC既往史的非乳头状UC。此外,BUC细胞核均匀,异型性程度低于非BUC,细胞角蛋白20反应性降低或阴性。UC的巢状和微囊性变体免疫组化染色表现为BUC。浸润性非BUC通常为乳头状,具有明显的细胞学异型性和多形性,占大多数pT1 UC。BUC的膀胱周围浸润、淋巴结转移和远处转移率高于非BUC。102例根治性膀胱切除标本中,所有9例原位UC缺失/残留极少的病例均来自浸润性非BUC。由于这种侵袭性行为、独特的免疫组化特征和主要的非乳头状结构,BUC与非BUC相区别。我们的发现与最近的研究一致,这些研究确定了一种具有基底细胞和管腔细胞分子谱分子表达的肌肉浸润性UC亚型。我们的研究进一步支持将浸润性UC分为这些具有不同生物学行为的亚型,这可能有助于制定更好的治疗策略。